The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the 503A Bulk Drug Substances List, reversing staff concerns over limited clinical data, immunogenicity risks, and adverse event reports. This non-binding step followed the peptide's removal from Category 2 earlier in April 2026 and opens a formal notice-and-comment rulemaking process that historically requires eight to twelve months before any change takes effect. Trader consensus reflects the advisory outcome as progress yet assigns lower near-term probability to swift Category 1 placement, given procedural timelines, committee composition scrutiny, and the FDA's discretion to diverge from panel recommendations. No final agency decision has been announced as of mid-September 2026.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoNOWE
Dec 31, 2026
December 31, 2026
55%
$4,551 Wol.
December 31, 2026
$2,549 Wol.
55%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the 503A Bulk Drug Substances List, reversing staff concerns over limited clinical data, immunogenicity risks, and adverse event reports. This non-binding step followed the peptide's removal from Category 2 earlier in April 2026 and opens a formal notice-and-comment rulemaking process that historically requires eight to twelve months before any change takes effect. Trader consensus reflects the advisory outcome as progress yet assigns lower near-term probability to swift Category 1 placement, given procedural timelines, committee composition scrutiny, and the FDA's discretion to diverge from panel recommendations. No final agency decision has been announced as of mid-September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Rynek otwarty: Jun 22, 2026, 10:10 PM ET
Wolumen
$4,551Data zakończenia
Jan 1, 2027Rynek otwarty
Jun 22, 2026, 10:10 PM ETRozstrzygający
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the 503A Bulk Drug Substances List, reversing staff concerns over limited clinical data, immunogenicity risks, and adverse event reports. This non-binding step followed the peptide's removal from Category 2 earlier in April 2026 and opens a formal notice-and-comment rulemaking process that historically requires eight to twelve months before any change takes effect. Trader consensus reflects the advisory outcome as progress yet assigns lower near-term probability to swift Category 1 placement, given procedural timelines, committee composition scrutiny, and the FDA's discretion to diverge from panel recommendations. No final agency decision has been announced as of mid-September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Wolumen
$4,551Data zakończenia
Jan 1, 2027Rynek otwarty
Jun 22, 2026, 10:10 PM ETRozstrzygający
0x65070BE91...The FDA's Pharmacy Compounding Advisory Committee voted 8-6 with one abstention on July 23, 2026, to recommend adding BPC-157 to the 503A Bulk Drug Substances List, reversing staff concerns over limited clinical data, immunogenicity risks, and adverse event reports. This non-binding step followed the peptide's removal from Category 2 earlier in April 2026 and opens a formal notice-and-comment rulemaking process that historically requires eight to twelve months before any change takes effect. Trader consensus reflects the advisory outcome as progress yet assigns lower near-term probability to swift Category 1 placement, given procedural timelines, committee composition scrutiny, and the FDA's discretion to diverge from panel recommendations. No final agency decision has been announced as of mid-September 2026.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania